MONMOUTH JUNCTION, N.J., Dec. 2 /PRNewswire/ -- TYRX, Inc., a leader in the development and commercialization of convergent drug-device products, today announced the appointment of David Elliot, Jr. as Chief Operating Officer, responsible for commercial operations.
Mr. Elliot brings over 25 years of experience in the medical device industry. Mr. Elliot joins TYRX from Valam Corp., a privately held company focused on providing laser-based antimicrobial and vascular plaque destruction therapies, where he was President and CEO and remains a Board Director. Prior to Valam, Mr. Elliot was President, COO and Board Director of VistaCare, Inc., a publicly traded hospice care provider. Prior to VistaCare, Mr. Elliot was President, CEO and Board Director of The VASCLIP Company, a privately held medical device company that provides a less invasive surgical alternative to vasectomy. Prior to VASCLIP, Mr. Elliot was the Vice President of Sales and Marketing at Advanced Respiratory, Inc., a privately held company now owned by Hillenbrand Industries, Inc., that sold a proprietary FDA-approved medical device for patients with respiratory issues.
From 1996 to 2001, Mr. Elliot held two senior executive positions (Vice President, Global Marketing of Cardiac Rhythm Management and Director of Corporate Business Development) at St. Jude Medical. In 1987, Mr. Elliot began his career in healthcare executive management at Guidant Corporation, where during the following nine years he held different roles of escalating responsibility and was ultimately the director of Guidant Japan's Cardiac Rhythm Management division. Mr. Elliot earned a Bachelor of Arts in English from
"We are thrilled to have David join our management team," said Bill Edelman, President and CEO. "David's experience in the Cardiac Rhythm Management space, as well as his dem
|SOURCE TYRX, Inc.|
Copyright©2008 PR Newswire.
All rights reserved